Connect with us
Finance Digest is a leading online platform for finance and business news, providing insights on banking, finance, technology, investing,trading, insurance, fintech, and more. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Research Reports



The Non Melanoma Skin Cancer Market is expected to witness an escalation going forward. With health apps, biosensors, AI, VR, telehealth, robots, cloud computing, predictive analysis, and EHRs being rampantly used, there is nothing to hold the healthcare vertical from soaring high. The healthcare vertical, would, see its cash registers ringing on the count of digital IoT creeping in at a rapid pace.

The Non Melanoma Skin Cancer Market is expected to reach US$ 4.8 Billion at a CAGR of 6.4% from 2025. Tech-driven innovation is the trend that the healthcare vertical would be resting on in the forecast period. With precision medicine being the focal point, extensive research is being carried out in every arm of the healthcare vertical. The status quo is expected to stay unchanged even in the forecast period.

In a new report titled ‘Non-Melanoma Skin Cancer Treatment Market: Global Industry Analysis 2012 – 2016 and Forecast 2017 – 2025,’ Persistence Market Research analyzes the global non-melanoma skin cancer treatment market over an eight year forecast period 2017 – 2025 and throws light on the various factors impacting revenue growth of the market over the said period.

The report highlights the market forecasts for the different segments and presents deeper insights for informed decision making.

Get Going With Sample Of Non Melanoma Skin Cancer Market Report!

Company Profiles

  • Almirall S.A.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Elekta AB
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Varian Medical Systems, Inc.
  • Sensus Healthcare
  • iCAD, Inc.
  • Accuray, Inc.
  • Ion Beam Applications SA
  • Others.

Get A Customized Scope To Match Your Need Ask An Expert –

Region – High Prevalence of Non-Melanoma Skin Cancer in North America

North America is estimated to hold a market share of roughly 55% in the global non-melanoma skin cancer treatment market in 2017 and is anticipated to have the highest attractiveness index of 3.0 during the forecast period.

Non-melanoma skin cancer is more prevalent in senior citizens and the Population Reference Bureau estimates that Americans over the age of 65 will double to almost 100 million by 2060.

Treatment Type – Radiation Therapy Larger than Chemotherapy and Photodynamic Therapy

Radiation therapy is larger than chemotherapy and photodynamic therapy combined, making it imperative for key stakeholders in the non-melanoma skin cancer treatment market to focus on this treatment type. Radiation therapy is poised to be worth more than US$ 4.7 Bn by end 2025. Within radiation therapy, companies may wish to target superficial radiation therapy.

How About Re-Inventing The Methodical Wheel In The Non Melanoma Skin Cancer Market? Switch Over To The “Methodology” Tab! 

Indication – Basal Cell Carcinoma Dominates the Non-Melanoma Skin Cancer Treatment Market

Even though squamous cell carcinoma is predicted to record a higher CAGR of 6.4% from 2017-2025, it is unlikely to outpace basal cell carcinoma anytime soon as the latter is likely to value at approx. thrice the size of the former by end 2025.

The attractiveness index of basal cell carcinoma is 1.5, considerably larger than the 0.5 of squamous cell carcinoma during the same period.

End User – Hospitals Popular Channel in the Non-Melanoma Skin Cancer Treatment Market

The treatment modalities for non-melanoma skin cancer usually require expensive radiation therapy. Therefore, hospitals are preferred over ambulatory surgical centers and specialty clinics in the non-melanoma skin cancer treatment market. The hospital segment is expected to reach a value of US$ 2 Bn in 2017 itself.

Key Findings of the Non-Melanoma Skin Cancer Treatment Market Report

Non-melanoma skin cancer places a high economic burden on countries with minimal medical treatment options, particularly at the metastatic stage. Many pharmaceutical companies are now trying to develop treatment options for late-stage non-melanoma skin cancer.

In addition, companies seek to use their existing drugs to effectively tackle squamous cell and basal cell carcinoma. Major players such as Bristol-Myers Squibb, Genentech, and Merck are working on gaining approval for their drugs to treat non-melanoma skin cancer.

Keeping A Tab On Key Players In The Non Melanoma Skin Cancer Market? Go To “Purchase Now” To Decipher The Competitive Analysis In Our Non Melanoma Skin Cancer Market Report!

Regulatory authorities and governmental bodies worldwide are adopting a number of cost-containment measures in the developed world. They are shifting from a volume to value-based system and this is driven by steps taken by life sciences companies and governments.

The measures include profit and risk sharing, outcome-based pricing, competitive tendering, and price control. The value-based healthcare system strives to achieve maximum value for every dollar spent on healthcare and improve outcomes by way of integrated care pathways.

The system simultaneously levies pricing pressure on medtech and biopharmaceutical companies and could potentially impact R&D investment in crucial, lifesaving medical treatment technologies in the long run.

About us: Persistence Market Research

Contact us:

Persistence Market Research          
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales –


Continue Reading

Why pay for news and opinions when you can get them for free?

       Subscribe for free now!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Posts